Lilly declares fourth-quarter 2024 dividend

LLY 10.28.2024

Full Press ReleaseSEC FilingsOur LLY Tweets

About Gravity Analytica

Recent News

  • 10.30.2025 - Q3 2025 Earnings Call
  • 08.07.2025 - Q2 2025 Earnings Call
  • 05.01.2025 - Q1 2025 Earnings Call

Recent Filings

  • 01.14.2025 - 8-K Current report
  • 01.14.2025 - EX-99.1 EX-99.1

INDIANAPOLIS,Oct. 28, 2024/PRNewswire/ -- The board of directors ofEli Lilly and Company(NYSE: LLY) has declared a dividend for the fourth quarter of 2024 of$1.30per share on outstanding common stock.

The dividend is payable onDec. 10, 2024, to shareholders of record at the close of business onNov. 15, 2024.

About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visitLilly.comandLilly.com/news. F-LLY

Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about expected dividend payments and reflects Lilly's current beliefs and expectations. However, there are significant risks and uncertainties in pharmaceutical research and development, as well as in business development activities and capital allocation strategies related to the company's business and actual results may differ materially due to various factors. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with theUnited States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Refer to:

Jordan Bishop;jordan.bishop@lilly.com; 317-374-1878 (Media)

Joe Fletcher;jfletcher@lilly.com; 317-296-2884 (Investors)

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-declares-fourth-quarter-2024-dividend-302288753.html

SOURCEEli Lilly and Company

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com